PubMed HealthSearch

Biomedical subjects

D L Curry

Publications and source records attributed to D L Curry.

At least 19 recordsLinked to original sources

Norepinephrine sensitivity of the endocrine pancreas in aging F344 rats.

The effect of norepinephrine (NE) infusion on glucose-stimulated insulin secretion was evaluated in whole perfused pancreases isolated from 6-, 12-, and 26-month-old male Fischer 344 (F344) rats. Glucose-stimulated insulin secretion was significantly inhibited by NE in all age groups. There was no significant effect of aging on the sensitivity or magnitude of inhibition at any of the concentrations of NE. In contrast, vascular pressure attained during NE infusion was significantly less in the 26-month-old rats compared to 6- and 12-month-old animals. These results suggest that the adrenoceptor neuroeffector mechanism of the smooth muscle declines at a faster age-related rate than does the beta-cell's adrenoceptor mechanism.

Aging

Dietary sucrose enhances insulin secretion of aging Fischer 344 rats.

Male Fischer 344 rats, ages 6, 12 and 26 mo, were fed a diet containing either sucrose or cornstarch (66% by weight) for 4 mo. The effects of age and dietary sucrose on glucose-stimulated insulin secretion were evaluated in whole perfused pancreases and isolated islets of Langerhans, and by intra-arterial glucose administration. In addition, glucose responsiveness of beta-cells was measured by following the rate of glucose oxidation in isolated islets. There was no significant effect of age on glucose-stimulated insulin secretion of whole perfused pancreases and islets of Langerhans. There was, however, a significant main effect of sucrose feeding on insulin secretion. That is, whole perfused pancreases and islets of Langerhans isolated from rats fed sucrose vs. starch diets secreted more insulin in response to glucose. This effect was most pronounced in the 26-mo-old rats. In general, islet glucose oxidation rates, and responses to the in vivo glucose, did not differ among the groups. We conclude that alterations in glucose-stimulated insulin secretion with age more closely reflect changes in diet rather than aging per se.

Aging

Age and gender effects on insulin secretion and glucose sensitivity of the endocrine pancreas.

Glucose-stimulated insulin secretion was evaluated in whole perfused pancreases and islets of Langerhans (90 to 110 microns diam) isolated from female and male Fischer 344 (F344) rats aged 6, 12, and 26 mo. Total glucose-stimulated (11.1 mmol/l) insulin release of whole perfused pancreases from male rats did not differ among age groups. In contrast, insulin secretion of 26-mo-old female rats was significantly greater than 6- and 12-mo-old female rats. Insulin secretion by islets of Langerhans incubated in glucose concentrations of 11.1, 16.7, and 22.2 mmol/l was greater in male rats compared with age-matched female animals at all three ages, and was greater in 6-vs. 26-mo-old male rats. Insulin secretion of female rats revealed some significant differences among the age groups, although no clear pattern was evident. Sensitivity of the islets to glucose was estimated from the rate of glucose oxidation. At incubation medium glucose concentrations of 11.1 mmol/l or higher, no effect of gender was observed, although the glucose oxidation rate of islets from male 26-mo-old rats was greater than that of islets from gender-matched 6-mo-old rats. These data indicate that in both the whole perfused pancreas and isolated islets of Langerhans, glucose-stimulated insulin secretion is not significantly altered with age or gender in the F344 rat. However, it appears that maintenance of insulin secretory capacity by aging male rats is achieved by enhancement of beta-cell sensitivity to glucose.

Aging

Autonomic nervous system mediation of the pancreatic polypeptide response to insulin-induced hypoglycemia in conscious rats.

To investigate the neural regulation of pancreatic polypeptide (PP) secretion during hypoglycemia in the rat, insulin was administered to chronically cannulated rats, and plasma PP responses were compared between saline-treated animals and animals pretreated with a ganglionic blocking agent (hexamethonium), a muscarinic antagonist (atropine), combined alpha- and beta-adrenergic receptor blockade (propranolol + tolazoline), or combined adrenergic blockade + atropine. PP was measured using a new RIA which selectively detects PP in rat plasma. In control rats (n = 10), plasma PP increased from a baseline level of 30 +/- 3 pg/ml to 271 +/- 41 pg/ml during hypoglycemia (plasma glucose = 29 +/- 2 mg/dl) (delta PP = +241 +/- 42 pg/ml, P less than 0.0005), demonstrating that in rats, as in other species, insulin-induced hypoglycemia is a potent stimulus for PP release. PP only increased by 31 +/- 10 pg/ml during similar hypoglycemia in 7 hexamethonium-treated rats (P less than 0.01 vs. control animals). Thus, at least 90% of the PP response to hypoglycemia is neurally mediated. The plasma PP response to hypoglycemia was +85 +/- 24 pg/ml in atropine-treated rats (P 0.01 vs. control rats), suggesting that approximately 65% of the PP response is mediated via muscarinic acetylcholine receptors on the islet F cell. The PP response to hypoglycemia in rats with combined adrenergic blockade (delta = +168 +/- 32 pg/ml) was slightly, but not significantly smaller than that in control rats. The combination of combined blockade + atropine resulted in a PP response (delta = +26 +/- 7 pg/ml) to hypoglycemia that was similar to that in hexamethonium-treated rats (P less than 0.01 vs. control rats). These results suggest: 1) The PP response to hypoglycemia is predominantly the result of muscarinic, cholinergic activation. 2) There is a minor adrenergic contribution to the response. 3) The plasma PP response may be useful as an index of autonomic neural input to the islet during hypoglycemia.

Animals

Inhibition by cyclosporine of insulin secretion--a beta cell-specific alteration of islet tissue function.

We have reported the potent inhibitory effect of cyclosporine on glucose-induced insulin release in in vitro perfused pancreases. Suppression of both phases of release indicates inhibition of secretion and synthesis. Further studies were performed to examine the effect of high extracellular Ca2+ (4.875 mM). High Ca2+ failed to potentiate release in CsA-treated pancreases, thus we are focusing on the integrity of Ca(2+)-dependent signals in the beta cell. In this study, four groups of pancreases were perfused at 16.7 mM glucose: Control +/- somatostatin (SRIF) and CsA-treated +/- SRIF (60 nM). In control rats, the total 2-hr release decreased 40% with SRIF, from 42.7 +/- 5.5 to 25.5 +/- 3.9 micrograms/300 g body weight (P less than .05). In CsA-treated rats, release decreased 55% with SRIF, from 8.9 +/- 1.1 to 4.0 +/- 0.6 micrograms/300 g body weight. Further, at every time point of these CsA-treated rats, there was approximately 15% greater inhibition by SRIF than in controls. Pancreatic insulin contents were determined, indicating marked depletion of insulin stores in CsA-treated rats (190 +/- 9 vs. 76 +/- 5 micrograms/300 g body weight, P less than .01). Arginine-stimulated secretion of insulin and glucagon was also examined in control and CsA-treated pancreases. CsA exerted no effect on arginine-stimulated glucagon release, yet inhibited insulin approximately 50%. From these studies, we conclude that normal SRIF inhibitory mechanisms must be at least partially intact in CsA-treated pancreases during glucose-induced insulin release, and that CsA inhibition is specific for insulin release, as glucagon stores and arginine-stimulated glucagon release are unaffected by CsA.

Analysis of Variance

Neural regulation of glucose-stimulated insulin secretion in younger and older Fischer 344 rats.

Neural regulation of insulin secretion of in situ innervated perfused pancreases was evaluated in younger (5 months) and older (26 months) Fischer 344 rats. In one protocol, the central nervous system (CNS) was intact throughout the entire 120-min perfusion period. In the other protocol, the CNS was intact only through the first 20 min of the 120-min perfusion, whereupon the CNS was ablated via anoxia. In both protocols, a modified Krebs-Ringer buffer containing glucose at 200 mg/dl was perfused through the pancreas at a rate of 4.8 ml/min by using a constant flow perfusion pump. Insulin secretion (ng.min-1) of younger and older CNS-intact rats did not differ significantly. After the ablation of the neural regulation of the pancreas, glucose-stimulated insulin secretion of younger rats was significantly lower, relative to the average insulin secretion before ablation (i.e., min 1-20) of CNS-intact animals. This would suggest that the nature of neural control of insulin secretion in younger rats is potentiation. In contrast, insulin secretion of older CNS-ablated animals was similar, or generally increased, when the data were expressed either on an absolute or a relative basis to preablation values, respectively. Thus, these data suggest that the neural regulation of glucose-stimulated insulin secretion in younger versus older rats is significantly different.

Aging

Direct neural effect of lateral hypothalamic stimulation on insulin secretion by pancreases of normal and obese rats.

Perfusion of CNS intact pancreases with 200 mg/dl glucose with concomitant lateral hypothalamic area (LHA) stimulation significantly inhibited insulin secretion both in normal and obese rats. Sprague-Dawley, Zucker lean (FaFa) and Zucker obese (fafa) rats all responded in a similar manner, suggesting a general effect unrelated to metabolic state. Insulin secretion during mins 25-40 of perfusion was inhibited in Sprague Dawley, lean Zucker and obese Zucker rats by 31%, 42% and 33%, even though LHA stimulation took place from mins 20-25. Thus, the duration of inhibition was greater than the period of LHA stimulation, indicating that this pathway can induce prolonged changes in the responsiveness of the pancreas. The data presented in this study demonstrate that LHA stimulation, in the absence of humoral factors, results in a direct CNS-mediated suppression of insulin secretion which is relatively long lasting. This effect may illustrate a basic control mechanism by the CNS to regulate the endocrine pancreas.

Animals

Effects of mannose and fructose on the synthesis and secretion of insulin.

Synthesis-secretion coupling of insulin was determined in perfused pancreases stimulated for 3 h by various sugars. These monosaccharide stimuli included glucose alone at either 200 or 300 mg/dl; mannose or fructose alone at 1,200 mg/dl; or combinations of mannose and fructose or galactose and fructose at 600 mg/dl each. Glucose and mannose each promoted insulin synthesis and secretion. Mannose at 1,200 mg/dl produced synthesis-secretion coupling similar to glucose at 200 mg/dl. Fructose alone at 1,200 mg/dl failed to cause any significant release of insulin, but it did significantly increase beta cell insulin content. When mannose and fructose were combined at 600 mg/dl each, in the absence of glucose, they resulted in a synergistic effect on insulin secretion and an additive effect on insulinogenesis, which was in excess of, or equal to, the insulinotropic effect of glucose at 300 mg/dl. These results clearly establish that the synthesis and secretion of insulin can be uncoupled. Mannose primarily stimulates the putative beta cell glucoreceptor, and fructose signals the insulin biosynthetic pathway. When combined, these monosaccharides couple synthesis-secretion of insulin comparable to glucose. The data suggest that the uncoupling of insulin secretion and synthesis, which may contribute either independently or in combination to abnormalities in pancreatic function observed in various diabetic conditions can be studied using the isolated perfused pancreas model. Use of this relatively physiological experimental model should provide optimal opportunity to further investigate and identify cellular controlling signals regulating either insulin biosynthesis, insulin secretion, or the coupling of both mechanisms.

Animals

Direct effect of CNS on insulin hypersecretion in obese Zucker rats: involvement of vagus nerve.

It is hypothesized that the vagus nerve makes a major contribution to pancreatic insulin hypersecretion in the genetically obese rat (fa/fa) via direct pancreatic innervation. An in situ brain-pancreas perfusion model with intact pancreatic central nervous system (CNS) innervation was used in these studies. The dynamics of insulin secretion in response to a 40-min glucose stimulus (200 mg/dl) was investigated in CNS intact (INT), bilateral cervical vagotomized (VGX), and CNS functionally ablated (ABL) 11- to 12-wk-old homozygous lean (Fa/Fa) and obese (fa/fa) female Zucker rats. The overall pattern of insulin secretory dynamics from obese and lean rats was similar. However, insulin released during the entire 40-min perfusion period by pancreata from obese rats was significantly greater than in lean rats. In lean rats, there was no significant difference in insulin secretion from pancreata of CNS-INT, VGX, and ABL rats. In obese rats, CNS-INT pancreata secreted almost twice as much insulin as pancreata from obese ABL rats and four times as much insulin as CNS-INT lean rats. This demonstrates that hypersecretion of insulin in obese Zucker rats is comprised of a significant direct CNS component. Although vagotomy had little effect on CNS-INT lean rats, it reversed the CNS component of hypersecretion present in CNS-INT obese rats. Because insulin secretion in CNS-INT obese rats was lowered by vagotomy to that equivalent to values of CNS-ABL obese rats, this demonstrates a significant contribution by the parasympathetic nervous system to the hyperinsulinemia seen in the Zucker obese rat that is attributed to direct parasympathetic innervation of the pancreas.

Animals

Synthesis-secretion coupling of insulin. Effect of cyclosporin.

This study investigated the effects of cyclosporin (Cs) on insulin secretion and synthesis from the endocrine pancreas. With in vitro perfused pancreases from control and Cs-treated rats (1, 5, 10, or 25 mg.kg-1.day-1 for 2 wk), a dose-response relationship between Cs dose and inhibition of insulin secretion was demonstrated. Examination of the dynamic secretory response to a glucose stimulus (200 mg/dl) over a 3-h perfusion revealed an inhibition of all three secretory phases. Similarly, the ability of the pancreases to synthesize insulin decreased as a function of Cs dose. Reversibility of Cs toxicity on the pancreas was established by 2 wk after cessation of treatment. To evaluate the effect of Cs treatment in vivo, intravenous glucose tolerance tests were performed. Rats treated with 25 mg.kg-1.day-1 Cs for 2 wk had significantly lower k values (slope of log glucose concentration over time) than controls. At 10 mg.kg-1.day-1, although curves that appeared abnormal were observed, k values were not significantly different from those of controls. In summary, this study demonstrates the profound inhibitory effect of Cs on the endocrine pancreas.

Animals

Pancreatic hypersensitivity to glucose by young obese Zucker rats (fa/fa).

Insulin secretory response to glucose was investigated in 5- to 6-week-old male Zucker obese (fa/fa) and lean (Fa/Fa) rats using a pancreatic perfusion procedure. Blood glucose response to fasting was studied in lean and obese animals over 24 hours. Plasma glucose was slightly elevated in pentobarbital-anesthetized obese rats. However, plasma insulin was 4.6 times greater than that of leans. A hypoglycemic glucose stimulus (75 mg/dL) caused pancreata from obese animals to release 6 times more insulin than lean animals. Stimuli of 125 mg/dL (normoglycemic) and 600 mg/dL (hyperglycemic) caused hypersecretion of 8 and 5 times, respectively. Hypersecretion was not accounted for solely by the twofold increase in pancreatic insulin content. Obese animals had steeper decreases in plasma glucose than lean controls during seven to 13 hours of fasting. Hypersecretion by pancreata from young obese rats to physiological levels of glucose may result in hyperphagia in order to maintain normoglycemia.

Age Factors

Episodic release of insulin by rat pancreas: effects of CNS and state of satiety.

This study reports that insulin is secreted in an episodic manner in rats and that the characteristics of its release can be modified by the central nervous system (CNS) and state of satiety. The pancreata of male Sprague-Dawley rats were perfused using the in situ brain-pancreas technique under urethan anesthesia. Episodic insulin release under non-fasted conditions was not altered by the presence or absence of CNS innervation to the pancreas. Under these conditions the interpeak period was 5.9 and 6 min, respectively, and cycle length was 3.7 and 4 min. However, perfusions that were performed following an overnight fast demonstrated that the CNS is capable of modulating episodic insulin release. After fasting, when comparing CNS-ablated with -intact preparations, the period was shortened from 5.2 to 4.1 min (P less than 0.05), and the number of episodes per 90-min perfusion increased from 16.0 to 19.0 (P less than 0.05) when the pancreas was innervated by the CNS. Additionally, the effect of fasting on denervated pancreata resulted in a shortening of the cycle length, which was prevented when the CNS was functional. These results demonstrate that episodic insulin release can be modified by metabolic conditions and are subject to mediation by the CNS.

Animals

Stimulation of insulin secretion by beta-endorphins (1-27 & 1-31).

Synthetic human beta-endorphin potentiates insulin secretion by the isolated perfused rat pancreas when glucose is present in the perfusate at concentrations of either 125 or 200 mg/dl, whereas it fails to exert any effect on insulin secretion in the presence of a substimulatory concentration of 100 mg/dl. Similar potentiation of insulin secretion occurred in response to the 1-27 fragment (beta-endorphin1-27) of beta-endorphin. This transient potentiation lasts only 3 to 4 minutes, whereupon secretion returns toward control levels. Thus beta-endorphin produces only a transient spike-like secretory profile similar to the first phase of glucose-induced insulin secretion and it fails to produce any chronic insulin secretory response comparable to the second phase of insulin secretion. The insulinotropic effect of beta-endorphins occurred at concentrations varying from 0.1 to 5.0 ug/ml. These data suggest that beta-endorphin and beta-endorphin1-27 potentiate insulin secretion via a common beta cell opioid receptor, and that beta-endorphin may exert a paracrine control of insulin secretion. However, any such regulation appears to be via short-term alterations in the secretory process per se.

Animals

Effect of age on the insulin secretory response of perfused rat pancreas to arginine and tolbutamide.

In this study we compared the ability of perfused pancreases from 2 1/2 month-old and 12 month-old rats to secrete insulin in response to arginine or tolbutamide. The results indicate that the insulin secretory response to either secretagogue was between 25-85% greater (two-way analysis of variance, P less than .01) by perfused pancreases of older rats. On the other hand, islet cell mass was approximately three-fold greater in the pancreases of the older rats. When this difference in mass of insulin secretory tissue was taken into consideration, it became apparent that insulin secretion per beta cell by perfused pancreases of the older rats was only half that of the younger rats in response to either arginine or tolbutamide (two-way analysis of variance, P less than 0.001). Thus, the decline with age in the ability of the beta cell to secrete insulin, previously noted in response to glucose, involves other insulin secretagogues as well.

Aging